EnteroTrack Investor Deep Dive

EnteroTrack, based in Aurora, CO, has developed the Esophageal String Test (EST) — the only non-endoscopic method to screen and monitor Eosinophilic Esophagitis (EoE), reducing patient and payer costs by over 80% compared to endoscopic biopsy. With CAP/CLIA lab operations, Medicare and major insurer reimbursements, and 50+ clinics onboarded, the company has grown test volume 10x in the past year. Backed by 5 granted and 18 pending patents, unique antibodies, and over 7 years of clinical trials, EnteroTrack is scaling toward a $4B market, seeking $2.5M to reach $3M ARR and expand its diagnostic pipeline.

The RVC Deep Dive is a 90 minute virtual meeting held between company executive leadership, RVC Investors, and RVC staff. The purpose of this meeting is to cover all major due diligence questions such as business strategy, team, product, competition, IP, market, traction, key risks, and exit strategy. 

The structure of the meeting is as follows:

• Company Pitch (15 minutes)
• Guided Q&A w/ Investors (45 minutes)
• Investor Only Discussion (30 minutes)

To attend, you must be an accredited investor (net worth of at least one million US dollars, not including the value of one’s primary residence, or have made at least $200,000 each year for the last two years [or $300,000 together with his or her spouse if married] and have the expectation to make the same amount this year). We do not require a minimum investment.